You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Selective inhibitor of erastin induced ferroptosis (EC50 = 60 nM). Specifically inhibits Ras selective lethal compound -induced death, but not cell death induced by other oxidative lethal compounds and apoptosis-inducing agents. Inhibits ferroptosis in cancer cells; also inhibits glutamate-induced cell death in organotypic rat brain slices. Prevents erastin induced accumulation of cytosolic and lipid reactive oxygen species.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 262.35. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.81 mL||19.06 mL||38.12 mL|
|5 mM||0.76 mL||3.81 mL||7.62 mL|
|10 mM||0.38 mL||1.91 mL||3.81 mL|
|50 mM||0.08 mL||0.38 mL||0.76 mL|
References are publications that support the biological activity of the product.
Dixon et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 1060 PMID: 22632970
Louandre et al (2013) Iron-dependent cell death of hepatocellular carcinoma cells exposed to sora. Int.J.Cancer 133 1732 PMID: 23505071
Skouta et al (2014) FerroSTAT inhibit oxidative lipid damage and cell death in diverse disease models. J.Am.Chem.Soc. 136 4551 PMID: 24592866
If you know of a relevant reference for Ferrostatin 1, please let us know.
View Related Products by Product Action
Keywords: Ferrostatin 1, Ferrostatin 1 supplier, Selective, inhibitors, inhibits, erastin, induced, ferroptosis, RAS, selective, lethal, compound, RSL, ROS, Ferroptosis, 5180, Tocris Bioscience
1 Citation for Ferrostatin 1
Citations are publications that use Tocris products. Selected citations for Ferrostatin 1 include:
Bi et al (2019) Metadherin enhances vulnerability of cancer cells to ferroptosis. Cell Death Dis 10 682 PMID: 31527591
Do you know of a great paper that uses Ferrostatin 1 from Tocris? Please let us know.
Reviews for Ferrostatin 1
There are currently no reviews for this product. Be the first to review Ferrostatin 1 and earn rewards!
Have you used Ferrostatin 1?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
MAPK Signaling Scientific Review
MAP kinase signaling is integral to the regulation of numerous cellular processes such as proliferation and differentiation, and as a result is an important focus of cancer and immunology research. Updated for 2016, this review discusses the regulation of the MAPK pathway and properties of MAPK cascades. Compounds available from Tocris are listed.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.